CD10 expression in tumour and stromal cells of bladder carcinoma: an association with bilharziasis

Abstract

CD10 is a cell surface zinc metalloprotease expressed in a variety of normal cell types, including lymphoid precursor cells, germinal centre B lymphocytes and some epithelial cells. The aim of this study was to assess the prognostic value of CD10 in bladder carcinoma. The expression of CD10 was immunohistochemically assessed in 49 cases of primary bladder carcinoma in comparison with 10 non-neoplastic normal bladder mucosa specimens. 27 cases (55%) were tumour CD10(+) and tumour CD10 positivity was significantly correlated with advanced stage, larger tumor size, and shorter mean survival time. Extensive tumoral staining assessed by H score further documented the positive correlation of CD10 with worse prognostic factors in the whole group and its subdivisions (SCC and TCC), in addition to its significant association with bilharziasis in SCC. Only CD10-tumour positivity in the whole group proved to be an independent prognostic factor for overall survival by multivariate analysis. No significant value of stromal CD10 expression in the investigated bladder carcinoma cases was found. This study points to the prognostic value of neoplastic CD10 expression in bladder carcinoma and its possible importance in facilitating tumour invasion and metastasis. Bilharziasis could have a role in upregulation of CD10 expression in SCC.

CD10 expression in urothelial carcinoma of the bladder

“…The authors proposed that the higher level of CD10 expression in noninvasive carcinomas appears to inhibit cell invasion. In a more recent series of 49 cases by Abdou et al, CD10 expression significantly correlated with some parameters including advanced stage, tumor size, and shorter mean survival but not with grade [46]. The authors suggested that CD10 appears to be associated with tumor progression and that it could play a pivotal role in bladder cancer pathogenesis, a proposal also supported by our findings.…”

“…To date, only a few studies have investigated CD10 expression in urothelial carcinoma of the urinary bladder [43-46]. In the current study, we evaluated 371 urothelial carcinomas of the urinary bladder and sought to determine the correlation, if any, between IHC CD10 expression and histopathologic parameters including grade and stage and to find out whether CD10 expression could have a prognostic value in the assessment of urothelial cancer.…”

Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma

“…10,11 Moreover, immunohistochemical studies have revealed that this antigen is expressed in carcinomas of the gastrointestinal and genitourinary tracts and in some sarcomas and MMs. 12,13 Neoplastic CD10 expression has been reported to correlate with tumor progression and shorter patient survival periods in several malignancies such as bladder carcinoma, 14 upper urinary tract transitional cell carcinoma, 15 and pancreatic endocrine tumors. 16 However, studies on the prognostic potential of CD10 in human prostate cancer and diffuse large cell lymphoma have provided conflicting data, describing CD10 expression as favorable, [17][18][19] unfavorable, [20][21][22][23] or not a valid risk factor.…”

E-cadherin and CD10 expression in atypical hyperplastic and malignant endometrial lesions

“…It is widely distributed in the kidney, liver, small intestine, placenta, choroid plexus, brain, gonads, adrenal cortex and leucocytes [23]. It was reported that CD10 expression in cancer stromal cells is associated with neoplastic transformation, tumor progression and biological tumor aggressiveness [24][25][26]. In gynecologic pathology, CD10 is a sensitive marker to identify normal and neoplastic endometrial stromal cells [27].…”